Which other gram‑negative, non‑lactose‑fermenting, oxidase‑positive bacteria should be considered in the differential?

Gram-Negative, Non-Lactose-Fermenting, Oxidase-Positive Bacteria to Consider

The key organisms to consider in your differential are Stenotrophomonas maltophilia, Burkholderia cepacia complex, Achromobacter xylosoxidans, Alcaligenes spp., Sphingomonas paucimobilis, Elizabethkingia spp., and Chryseobacterium spp. 1, 2

Primary Pathogens by Frequency

Most Common

• Stenotrophomonas maltophilia - This is the most frequently isolated organism in this category, accounting for approximately 45% of non-pseudomonal, non-Acinetobacter non-fermenters in respiratory specimens 2
• Burkholderia cepacia complex - Second most common at approximately 12% of isolates 2

Less Common but Clinically Significant

• Achromobacter xylosoxidans - Accounts for approximately 9% of these isolates and is particularly important in immunocompromised and cancer patients 2, 3
• Sphingomonas paucimobilis - Also represents about 9% of isolates 2
• Alcaligenes spp. - Less frequent but emerging opportunistic pathogen 1
• Elizabethkingia spp. - Rare but increasingly recognized 1
• Chryseobacterium spp. - Uncommon opportunistic pathogen 1

High-Risk Patient Populations

These organisms preferentially infect specific patient groups:

• Immunocompromised patients (including those with malignancies)
• Cystic fibrosis patients
• Critically ill/ICU patients
• Patients with structural lung disease (bronchiectasis) 4, 1

Critical Clinical Pitfall

Do not dismiss these organisms as contaminants. When isolated from respiratory specimens, approximately 70% demonstrate true pathogenicity upon clinico-microbiological correlation 2. The key is correlating the isolation with clinical findings rather than automatically assuming colonization.

Resistance Considerations

All of these organisms exhibit intrinsic multidrug resistance through multiple mechanisms 1:

• β-lactamase expression
• Multidrug efflux pumps
• Aminoglycoside-modifying enzymes
• Target site alterations

This makes empiric coverage challenging and necessitates targeted therapy based on susceptibility testing once identified 5, 4.

Practical Identification Approach

When you encounter a gram-negative, non-lactose-fermenting, oxidase-positive organism:

1. Initial grouping uses motility, oxidase, and OF glucose reactions 6

2. Additional tests for speciation include:

   • Growth at 42°C
   • Fluorescein production
   • DNase activity
   • Esculin hydrolysis
   • Arginine dihydrolase
   • Nitrate reduction 6

3. Automated systems can assist but have variable accuracy (61-80% depending on system) for oxidase-positive non-fermenters, often requiring supplemental testing 7

Treatment Implications

Timely identification and appropriate antibiotic coverage based on susceptibility testing results in clinical improvement in approximately 88% of cases 2. This underscores the importance of:

• Not ignoring these isolates
• Pursuing definitive identification
• Obtaining susceptibility testing
• Correlating with clinical presentation before dismissing as colonization

The guideline-based approach for empiric coverage of gram-negative pneumonia recommends antipseudomonal agents 4, but once these specific organisms are identified, treatment must be tailored to susceptibility results rather than relying on empiric regimens 5.